Enalkiren
Also known as: A-64662, A64662
Source Enalkiren at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Enalkiren (A-64662) is an early peptidomimetic renin inhibitor developed in the late 1980s and early 1990s by Abbott Laboratories. It was investigated as an antihypertensive agent but was never approved for clinical use, primarily due to poor oral bioavailability requiring parenteral administration and the subsequent development of more drug-like small-molecule renin inhibitors (e.g., aliskiren).
Mechanism of Action
Competitive inhibitor of renin, the aspartyl protease that cleaves angiotensinogen to angiotensin I. By blocking renin, enalkiren reduces the generation of angiotensin I and subsequently angiotensin II, leading to vasodilation and decreased aldosterone secretion.
Routes of Administration
Goals & Uses
- Antihypertensive effectCardiovascularModerate
- Heart failure managementCardiovascularLow
- RAAS suppressionCardiovascular/EndocrineModerate
Contraindications
- Hypersensitivity to enalkiren or excipientsImmunologicHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Bilateral renal artery stenosisVascular/RenalHigh
Adverse Effects
- Injection site reactionsLocalCommon
- HypotensionCardiovascularCommonLow blood pressure
- Renal function impairmentRenalUncommon
- HyperkalemiaElectrolyte ImbalanceUncommon
Drug Interactions
- Potassium-sparing diuretics / potassium supplementsModerate
- ACE inhibitors / ARBsHigh
- NSAIDsModerateMay increase renal risk in susceptible patients
Population Constraints
- Patients with renal impairmentOrgan ImpairmentRelative
- Pregnant womenReproductiveAbsolute
- Volume-depleted patientsCardiovascularRelative
Regulatory Status
- European UnionUnapprovedNo regulatory submission or approval; remained a research compound.
- United StatesUnapprovedInvestigated in Phase II clinical trials; never submitted for or received FDA approval.
- United KingdomUnapprovedNo approval; used only in clinical research settings.
Never received regulatory approval in any jurisdiction. Remained a research/investigational compound. Development was discontinued in favor of orally bioavailable renin inhibitors.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Enalkiren?
Enalkiren (A-64662) is an early peptidomimetic renin inhibitor developed in the late 1980s and early 1990s by Abbott Laboratories. It was investigated as an antihypertensive agent but was never approved for clinical use, primarily due to poor oral bioavailability requiring parenteral administration and the subsequent development of more drug-like small-molecule renin inhibitors (e.g., aliskiren).
What is Enalkiren used for?
Enalkiren is educationally associated with: Antihypertensive effect, Heart failure management, RAAS suppression. Educational only — not medical advice.
How is Enalkiren administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Enalkiren?
Reported adverse effects include: Injection site reactions, Hypotension, Renal function impairment, Hyperkalemia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Enalkiren?
Recorded contraindications: Hypersensitivity to enalkiren or excipients, Pregnancy, Bilateral renal artery stenosis. Consult a qualified clinician before use.